NCT02323854: A reported trial by Medtronic - MITG
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02323854 |
|---|---|
| Title | The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 31, 2015 |
| Completion date | March 13, 2017 |
| Required reporting date | March 13, 2018, midnight |
| Actual reporting date | March 9, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |